Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corgenix Medical, a developer and marketer of diagnostic test kits, has announced its collaboration with BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel molecular-based diagnostics.
Subscribe to our email newsletter
Under the collaboration, Corgenix’s AtherOx products will be included in studies conducted by BG Medicine to predict near-term risk of first myocardial infarction.
Under the terms of the collaboration agreement, Corgenix will provide several of its products for the studies conducted by BG Medicine, including the IgG Anti-AtherOx kit, which is currently FDA cleared, as well as the investigational Anti-AtherOx IgM and AtherOx kits.
Corgenix may use the data generated by BG Medicine with the AtherOx technology products for regulatory and commercialization purposes in exchange for certain considerations.
Douglass Simpson, president and CEO of Corgenix, said: “We are extremely pleased with this opportunity to evaluate the role of our AtherOx products in this important indication.”